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Abstract
NADH:ubiquinone oxidoreductase (complex I) is the largest multiprotein complex of the mitochondrial respiratory chain. His-tagged
complex I purified from the strictly aerobic yeast Yarrowia lipolytica exhibited electron transfer rates from NADH to n-decylubiquinone of
less than 2% when compared to turnover numbers calculated for native mitochondrial membranes from this organism. Reactivation was
observed upon addition of asolectin, purified phospholipids and different phospholipid mixtures. Maximal activities of 6–7 Amol NADH
min1 mg1 were observed following incubation with a mixture of 76% phosphatidylcholine, 19% phosphatidylethanolamine and 5%
cardiolipin. For full reactivation, 400–500 phospholipid molecules per complex I were needed. This demonstrated that the inactivation of
complex I from Y. lipolytica by general delipidation could be fully reversed simply by returning the phospholipids that had been removed
during the purification procedure. Thus, our homogeneous and highly pure complex I preparation had retained its full catalytic potential and
no specific, functionally essential component had been lost. As the purified enzyme was also found to contain only substoichiometric
amounts of ubiquinone-9 (0.2–0.4 mol/mol), a functional requirement of this endogeneous ubiquinone could also be excluded.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
As the first multiprotein complex involved in the build-
up of the proton-motive force in mitochondria, NADH:ubi-
quinone oxidoreductase (EC 1.6.99.3, complex I) has a
central position in oxidative phosphorylation. Mitochondrial
complex I catalyses a two-electron transfer from NADH to
ubiquinone linked to the translocation of four protons across
the inner mitochondrial membrane [1]. In contrast to its
central role in oxidative phosphorylation and the discovery
of an increasing number of human diseases linked to this
enzyme [2,3], neither the details of the molecular structure
nor the molecular mechanism coupling electron transfer to
proton transport across the inner mitochondrial membrane
are known. As a new approach to solve some of these open
questions, we have established the strictly aerobic yeast
Yarrowia lipolytica as a model system that offers a set of
molecular genetic tools similar to those known for the yeast
Saccharomyces cerevisiae: we constructed Y. lipolytica
strains, in which genes encoding essential nuclear encoded
subunits of complex I were deleted, allowing us to inves-
tigate the effect of mutations in the respective subunit
expressed on a single copy Escherichia coli/Y. lipolytica
shuttle vector [4–8]. Furthermore, we attached a His6-tag to
the C-terminus of the 30 kDa subunit (encoded by the
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NUGM gene) which allows for rapid isolation of highly pure
and homogeneous complex I from Y. lipolytica [9,10]. As
judged by the complex I specific electron transfer from
NADH to the artificial electron-acceptor hexaammineruthe-
nium(III)-chloride (HAR), the specific activity is increased
by a factor of 70 during purification from mitochondrial
membranes [9]. However, the specific electron transfer rate
from NADH to the artificial acceptor n-decylubiquinone
(DBQ) does not increase concomitantly, but is even reduced
when compared to native mitochondrial membranes. Since
the NADH:HAR activity of complex I was assigned to a
three-subunit subcomplex (flavo protein ‘FP’) of the so-
called peripheral arm [11], while the NADH:DBQ activity
represents the activity of the whole complex, one might
conclude that an important factor was lost upon purification.
We already excluded the loss of non-covalently bound FMN
or EPR-detectable iron sulfur clusters [4,10]. As there are
also no indications for the loss of subunits, further candi-
dates are bound phospholipids or a tightly bound ‘func-
tional’ ubiquinone that had been postulated as an integral
part in several hypothetical models for the catalytic mech-
anism [12–14]. Therefore, we have determined the phos-
pholipid and ubiquinone content in highly pure preparations
of His6-tagged complex I of Y. lipolytica and have analyzed
the effects of phospholipids on catalytic activity of isolated
complex I.
2. Materials and methods
2.1. Materials
The following phospholipids were purchased from Sigma
(all as solid powders): cardiolipin (CL, sodium salt, from
bovine heart, purity > 98%), phosphatidylethanolamine
(PE, type III, from egg yolk, purity >98%) and phosphati-
dylcholine (PC, type XVI-E from fresh egg yolk, purity
>99%). All other lipids were purchased from Avanti Polar
Lipids (Alabaster, AL) as solid powder (asolectin=total
soybean extract with 20% lecithin; referred to in general
as 20%; two partially purified soybean extracts with 45%
and 95% lecithin, usually referred to as 45% and 95%,
respectively) or chloroform solutions (‘polar extract’ of the
total chloroform/methanol extract of soybean; EYPC, purity
>99%; EYPE, purity >99%; Plant PC from soybean, purity
>99%; 6:0 PC, purity >99%; 8:0 PC, purity >99%).
Dodecyl-h-D-maltoside (DDM) and octyl-h-D-glucopyrano-
side (OG) were obtained from BIOMOL and chelating
Sepharose from Pharmacia. Silica 60 TLC plates were
purchased from Merck, Darmstadt (Germany). All other
chemicals were purchased from Sigma.
2.2. Analytical methods
Protein concentrations were determined according to a
modified Lowry protocol [15]. The phospholipid content of
purified complex I was determined as total organic phos-
phate content following the protocol of Ref. [16]. For the
analysis of bound phospholipids, about 100–200 Ag of
purified complex I (pools after Ni-affinity chromatography
and subsequent gel filtration, respectively; see below) were
extracted with 20 volumes of chloroform/methanol (2:1).
Thin-layer chromatography (TLC) of the chloroform/meth-
anol extract and subsequent phospholipid staining by
molybdenum spray was performed as detailed in Ref.
[17]. For the determination of the ubiquinone content,
ubiquinone was extracted from 7 to 8 mg of purified
complex I according to a protocol in Ref. [18], modified
by replacing light petroleum with n-hexane. In some cases,
complex I was degraded by the addition of 1–2 units of
proteinase K (Sigma P-8044, EC 3.4.21.64) prior to hexane
extraction. Proteolysis took place for about 12 h at 56 jC.
The residue of the hexane phase was dissolved in ethanol
and analyzed by reversed phase HPLC (detection at 275 nm)
according to Ref. [19], using a HiBarR prepacked Column
RT 250-4, LiChropherR 100 RP-18 (5 nm) from Merck and
the following solution as mobile phase: 7 g NaClO4 H2O in
1000 ml ethanol/methanol/70% HClO4 (700:300:1). The
column was calibrated by varying amounts of Q9 from
Torulopsis utilis (former Candida utilis) (90–95% purity)
or synthetic Q10 (minimal purity 98%) from Sigma. The
actual concentrations of the standards were determined
spectrophotometrically at 275 nm, ered-ox=12,500 M
1
cm1 [20]. The stoichiometry between bound ubiquinone
and complex I was calculated assuming a molecular mass
of 890 kDa for complex I [4].
2.3. Yeast growth and preparation of mitochondrial
membranes
Y. lipolytica strain PIPO was grown overnight at 27 jC in
a 10-l Biostat E fermenter (Braun, Melsungen) in modified
YPD medium (2.5% glucose, 2% bactopeptone, 1% yeast
extract). The construction of this strain is detailed elsewhere
[10]. Briefly, this strain contains a chromosomal copy—
introduced by homologous recombination with plasmid
pNK1.2 as described in Ref. [9]—of the modified NUGM
gene, encoding a C-terminally His-tagged version of the 30
kDa subunit. Mitochondrial membranes from strain PIPO
were prepared following the protocol of Ref. [21] with the
modification detailed in Ref. [9].
2.4. Purification of complex I
For the purification of complex I, mitochondrial mem-
branes of Y. lipolytica strain PIPO were solubilized with
dodecyl maltoside as described previously [9]. Purification
was achieved by Ni-affinity chromatography, followed by
gel filtration as detailed in Ref. [9] with a minor modifica-
tion: the imidazole concentration of the buffer used for the
equilibration and washing of the Ni2+-NTA column was
reduced to 55 mM. The combined complex I containing
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peak fractions of the gel filtration were concentrated to 3–
10 mg/ml by centrifugation through Vivaspin cartridges
(MWCO 100,000; Vivascience, UK) and stored in liquid
nitrogen.
2.5. Preparation of lipid–detergent mixtures
Two different protocols were used for the preparation of
solubilized phospholipids. For larger quantities, 70 mg of
solid phospholipids where sonicated in 7 ml buffer (20 mM
K+/Hepes pH 7.2 or 20 mM K+/Mops pH 7.2, respectively,
containing 50 mM KCl and 1.6% OG; no buffer-specific
differences were observed) until the solution was clear.
Dilutions of this stock solution were prepared with the same
buffer. For smaller quantities (and when the lipids were
supplied as solutions in chloroform), an aliquot of the
phospholipids in chloroform was added to a glass vial and
the solvent was evaporated under a stream of argon. After
another hour under vacuum the phospholipids were then
dissolved to a concentration of 10 mg/ml in the above-
mentioned buffer. Dilutions were prepared in the same
buffer.
2.6. Determination of catalytic activity
NADH:HAR activity of purified complex I was meas-
ured at 30 jC in a buffer containing 20 mM Na+/Hepes pH
8.0, 250 mM sucrose, 2 mM EDTA and 2 mM NaN3 using 2
mM HAR and 200 AM NADH as substrates. For the
determination of NADH:ubiquinone oxidoreductase activ-
ity, 60 AM DBQ and 100 AM NADH were used as
substrates, following the protocol described previously [4].
NADH oxidation rates were recorded with a Shimadzu
Multi Spec-1501 diode array spectrophotometer (e340–400
nm=6.1 mM
1 cm1[22]). To analyze the effect of the
different phospholipids and lipid mixtures, aliquots of
different stock solutions were added to the buffer after
starting the reaction with DBQ (controls) or to the complex
I preparation prior to the addition of the enzyme to the assay
buffer. In the latter case, the concentrated enzyme–lipid–
detergent mixture (usually 5 Al) was preincubated for 20
min on ice, if not indicated otherwise.
3. Results
3.1. Phospholipid and ubiquinone content of purified
complex I from Y. lipolytica
Complex I purified from the Y. lipolytica strain PIPO
carrying a chromosomal copy of the gene coding for the
His-tagged 30 kDa subunit exhibited very low NADH:ubi-
quinone oxidoreductase activities (0.1–0.2 Amol min1
mg1). Similar values were found previously for a strain
carrying a plasmid-borne copy of the His-tagged 30 kDa
subunit [9] and for the wild-type complex purified by
conventional chromatographic techniques [4]. Since activity
could be largely restored by reconstitution of the complex
into asolectin proteoliposomes [9], delipidation seemed to
be the most likely explanation for inactivation. However,
asolectin is a crude lipid mixture derived from soybean by
total chloroform/methanol extraction and partitioning
against deionized water. In addition to various phospholi-
pids, it contains a number of poorly characterized lipophilic
components. Therefore, it still seemed possible that rather
than the phospholipids of asolectin, a quinoid component
was responsible for the observed reactivation.
We analyzed the phospholipid and ubiquinone content of
our complex I preparation. The phospholipid content deter-
mined as total organic phosphate varied between 26 and 66
mol phosphate per mol complex I in different batches (n=4).
The analysis of a chloroform/methanol extract of our
preparation by TLC revealed that the phospholipids bound
to complex I after detergent solubilization and purification
represented the three major classes of phospholipids of the
inner mitochondrial membrane/CL, PC and PE (results not
shown).
For the determination of ubiquinone content, about 9
nmol of purified complex I were extracted with n-hexane/
methanol/70% HClO4 (69%/29.5%/1.5%). The residue of
the hexane phase was analyzed by reversed phase HPLC
(Fig. 1). Since Y. lipolytica contains ubiquinone-9 (Q9) [23],
commercially available Q9 from T. utilis was used as a
standard. When the Q9 standard from T. utilis was applied to
Fig. 1. Ubiquinone-9 extracted from purified complex I from Y. lipolytica.
A ubiquinone-9 standard from T. utilis and the residue of the n-hexane
extract of a complex I preparation from Y. lipolytica were applied to
reversed phase HPLC as detailed under Materials and methods. The
retention profiles were monitored at 275 nm with identical sensitivity. Two
representative chromatograms are presented in scale: (A) 0.155 nmol
ubiquinone-9 standard; (B) 1/10 of the total n-hexane extract of 8.7 nmol
complex I.
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reversed phase HPLC, one prominent peak detected at 275
nm with a retention time of 23.1 min was observed (Fig.
1A). Minor fluctuations of the automatically determined
peak values occurred in different runs of the same standard.
A peak with essentially the same retention time was detected
in the n-hexane extract of purified complex I (Fig. 1B).
Other peaks were observed with retention times between 3.5
and 18 min. None of these peaks could be related to
ubiquinone-10 (Q10), which was found to elute with a
retention time of around 31.2 min (not shown). Unfortu-
nately, the Q9 content in our preparation was too low for
spectroscopic characterization. Based on a calibration of the
peak areas with different Q9 standard runs, we initially
calculated a Q9 content of 0.07 mol per mol complex I for
our preparation. However, we observed a precipitation of
protein in the hexane phase that interfered with complete
separation of the hexane from the methanol phase. Probably,
the majority of the hydrophobic subunits of complex I
stayed in the hexane phase. This could be largely overcome
by total proteolysis of complex I. Following 12 h degrada-
tion of complex I with proteinase K prior to hexane–
methanol-extraction, much less precipitated protein was
found in the hexane phase. All major subunits of complex
I were degraded as judged by polyacrylamide electropho-
resis (not shown). After proteolysis, the Q9 content deter-
mined in the same preparation increased to 0.2 mol per mol
complex I. In a different batch of protein 0.4 mol per mol
complex I were found. In summary, we conclude that
complex I purified from Y. lipolytica contained amounts of
Q9 that were clearly substoichiometric.
3.2. Activation of purified complex I by detergent solubilized
asolectin
In a first experiment, we investigated the effect of
asolectin on the NADH:DBQ activity of complex I puri-
fied from Y. lipolytica mitochondrial membranes (Fig. 2).
The basal NADH:DBQ activity in this representative
experiment was about 0.2 Amol min1 mg1 and did not
increase markedly upon addition of 2.5 Al of 1.6% OG
(final concentration as in all other measurements 0.004%;
trace A, 0.25 Amol min1 mg1), the detergent used for
solubilization of the phospholipids. If solubilized asolectin
was added at a lipid to protein ratio of about 3.5:1(w/w)
during the assay, only a minor activation to 0.5 Amol
min1 mg1 could be observed (trace B). However, a
pronounced stimulating effect was observed, if the purified
complex I was preincubated at a concentration of 1.4 mg
ml1 with 3.5:1 g/g solubilized asolectin (trace C) prior to
addition to the cuvette. Activation was also observed when
complex I purified in the presence of 0.1% dodecylmalto-
side was preincubated with preformed liposomes (not
shown).
To explain the large difference between addition of and
preincubation with asolectin, one has to consider that upon
addition of the detergent–phospholipid mixture to the large
volume of the assay buffer, the OG- and DDM-concentra-
tions (0.14 mM and <25 AM, respectively) drop far below
their critical micellar concentration (20–25 mM, equivalent
to 0.6–0.7% for OG and 0.1–0.6 mM, equivalent to 0.03–
0.005% for DDM) and liposomes or mixed micelles are
instantly formed. Therefore, the interaction between com-
plex I present in the assay buffer and subsequently added
phospholipids is limited. A different situation occurs when
the lipids are preincubated with the enzyme. Upon dilution
into the assay buffer, detergent-containing proteoliposomes
or at least mixed protein–detergent–phospholipid micelles
are formed in which a thorough interaction between com-
plex I and phospholipids is possible. While we can’t
distinguish between these two possibilities, we can at least
exclude that tightly coupled proteoliposomes were formed
since the addition of uncouplers (FCCP) had no effect on the
NADH:DBQ activity (results not shown). The highest
NADH:DBQ activity observed in the presence of asolectin
(about 7 Amol min1 mg1) was comparable to the highest
value observed previously following reconstitution of Y.
lipolytica complex I into asolectin proteoliposomes by the
detergent removal technique (6.7 Amol min1 mg1, [9]).
Therefore, the procedure described here can be considered a
fast and material-saving method to investigate the effect of
different phospholipids on complex I activity. Activation of
purified complex I by preincubation with solubilized aso-
lectin was essentially complete after a few seconds. How-
ever, analysis of the time dependence of activation revealed
an additional slight increase of activity by extending the
preincubation time up to 20 min (not shown). Therefore, a
20 min preincubation time was used routinely in further
experiments.
Fig. 2. Stimulating effect of asolectin on the NADH:DBQ-activity of
complex I. For the representative measurements shown, the activity of
purified complex I was monitored at 30 jC. Total spectra in the range from
340 to 400 nm were recorded (1 nm intervals). Time courses of the
difference A340 minus A400 are shown. Enzyme (6.7 Ag) was added to 1 ml
of assay buffer containing 100 AM NADH before the measurement. The
reaction was started by the addition of 60 AM DBQ (black solid arrows).
OG or asolectin in OG were added as indicated. (A) Control with addition
of 0.004% OG. (B) Addition of 25 Ag solubilized asolectin and 0.004%
OG. (C) Complex I preincubated with 25 Ag asolectin for 20 min on ice.
The numbers indicate activities in Amol min1 mg1.
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3.3. Phospholipid specificity of reactivation
Using the protocol established for asolectin, the effect
of different partly purified asolectins and purified phos-
pholipids on the NADH:DBQ activity of complex I was
investigated. Depending on the batch of purified complex
I, maximal activities of 3–7 Amol min1 mg1 could be
reached. Therefore, the effects of different phospholipids
were compared within the same batch of enzyme. Fig. 3
summarizes the results for a typical preparation exhibiting
a maximal activity of 5.8 Amol min1 mg1. Comparable
results were obtained with other complex I preparations.
At a protein-to-lipid-ratio (w/w) of about 1:1, activation by
preincubation with the 20%, 45% and ‘polar extract’
asolectin was comparable, almost reaching 5 Amol min1
mg1. According to the manufacturer, these ‘soybean lipid
extracts’ all contain variable amounts of PC, PE, phospha-
tidylinositol (PI), phosphatidic acid (PA) and lyso PC as
well as up to 37% (in the case of the ‘total extract’)
components which are listed as ‘other’. In addition, ‘aso-
lectins’ contain between 10% and 25% CL [24,25], which
could be easily detected by TLC and molybdenum staining
(results not shown). When asolectin with a higher PC
content (95%) was used, an activity of only 3.2 Amol
min1 mg1 was observed, which compared well with
activities of 3.1–4.2 Amol min1 mg1 that were obtained
using HPLC-purified PC from different sources or PE from
egg yolk. Slightly higher activities around 4.5 Amol min1
mg1 were observed if an 80:20 mixture of PE and PC
was used. If CL alone was used for activation, a maximal
activity of only 1.5 Amol min1 mg1 was obtained.
However, preincubation with a mixture of 76% PC, 19%
PE and 5% CL, the three main phospholipids of the inner
mitochondrial membrane [26], resulted in maximal activa-
tion to 5.8 Amol min1 mg1 for this batch of purified
complex I. In contrast, almost no stimulation was observed
after addition of the synthetic short-chain phospholipids
6:0 PC and 8:0 PC.
From these data we conclude that complex I from Y.
lipolytica purified by affinity chromatography can be fully
reactivated simply by returning PC, PE and CL, the phos-
pholipids removed by the purification procedure. Thus, no
specific factor required for NADH:ubiquinone oxidoreduc-
tase activity was lost during purification and had caused the
observed inactivation.
3.4. Amount of phospholipid required for activity
In our initial experiments with different asolectin frac-
tions, we observed that the stimulation of NADH:DBQ
activity depends on the amount (ratio) of added lipid. For
a detailed analysis, we measured the dependence of activity
on the lipid-to-protein-ratio for several purified lipids (Fig.
4). With different phospholipids, we found that the maximal
activity was reached at a ratio between 450 and 900 mol of
phospholipids added per mol complex I. The value for
different PCs (purified from egg yolk (two different sources)
and from soybean) was around 450:1, while with egg yolk
PE the maximal activity was reached at a ratio of around
870:1. At higher ratios (>1000:1), some reduction of the
NADH:DBQ activity was observed in most cases. A some-
what different picture emerged for purified cardiolipin (Fig.
5). In this case maximal activity was reached when about
100 mol of cardiolipin were added per mole of purified
complex. At higher concentrations, a sharp drop in activity
Fig. 3. Stimulating effects of different asolectins and purified phospholipids
on the NADH:DBQ activity of complex I. Lipids (5 Ag) were preincubated
with 6.8 Ag of purified complex I. For experimental conditions see legend
of Fig. 2. AS PL, ‘polar lipid extract’ of asolectin (‘total’ chloroform/
methanol extract of soybean containing 20% lecithin, precipitated with
acetone and then extracted with diethyl ether); AS 20%, AS 45% AS 95%,
different asolectin fractions containing 20%, 45%, 95% of lecithin (PC),
respectively; EYPC 1, egg yolk PC from Avanti; EYPC 2, egg yolk PC
from Sigma; EYPE, egg yolk PE; EYPC/PE, 80% EYPC/20% EYPE; CL,
cardiolipin; EYPC/PE+CL, 76% EYPC/ 19% EYPE/5% CL; 6:0 PC, 1,2
dihexanoyl-sn-glycero-3-phosphocholine; 8:0 PC, 1,2 dioctanoyl-sn-glyc-
ero-3-phosphocholine. For details see Results.
Fig. 4. Dependence of the NADH:DBQ activity on the amount of added
phospholipids. Increasing amounts of purified phospholipids were
preincubated with 6.8 Ag of purified complex I. Experimental conditions
as indicated in Fig. 2. n EYPC from Avanti (100%=3.52 Amol min1
mg1) 5EYPC from Sigma (100%=3.85 Amol min1 mg1) E
soybean PC (100%=3.53 Amol min1 mg1) . EYPE (100%=4.19
Amol min1 mg1).
S. Dro¨se et al. / Biochimica et Biophysica Acta 1556 (2002) 65–72 69
was observed, resulting in an almost bell-shaped curve in
the half-logarithmic diagram (Fig. 5). This inhibitory effect
of higher concentrations might be responsible for the
relatively low maximal activity obtained with cardiolipin
that is specifically enriched in the inner mitochondrial
membrane of eukaryotic cells [27].
4. Discussion
There are several recent reports that describe the
purification of largely delipidated complex I from mito-
chondrial membranes of different sources [4,9,28–30].
Preparations with low lipid contents are a prerequisite
for crystallisation of complex I. Thus, their functional
integrity is critical for the interpretation of any X-ray
structures that will be based on such preparations. In all
cases however, the catalytic activity—as judged by elec-
tron transfer from NADH to artificial ubiquinone deriva-
tives (usually Q1 or DBQ)—was reduced dramatically
upon solubilization by various non-ionic detergents (e.g.
Triton X-100 or dodecylmaltoside) and subsequent purifi-
cation of the complex. In some reports, partial reactivation
to varying extents by the addition of phospholipids or by
reconstitution into proteoliposomes was mentioned as a
side remark [4,9,29,30]. More detailed studies on the
phospholipid requirements of bovine complex I date back
more than 20 years [31–33] and were performed with
enzyme preparations using ionic detergents like cholate
which always leave a rather large number of phospholipid
molecules and other hydrophobic components like ubiq-
uinone bound to the complex. Still, these preparation
protocols also result in marked activity loss and full
recovery by the addition of phospholipids was never
observed [32,33]. It remained unclear at the time whether
this was due to some irreversible damage to the complex
or partial removal of subunits or an unknown factor like a
special phospholipid or endogeneous ubiquinone that was
not replenished with the phospholipid mixtures used for
reactivation.
The proposal that complex I might contain a still
unidentified redox cofactor ‘X’ in its hydrophobic part
[34] and the even greater activity loss observed with
monodisperse preparations needed for crystallisation
prompted us to carefully analyze the correlation between
lipidation state, ubiquinone content and catalytic activity for
complex I purified from Y. lipolytica mitochondria.
The delipidating conditions during the purification
procedure were found to leave only around 50 phospho-
lipids bound to the essentially inactive complex (NADH:-
ubiquinone oxidoreductase activity <2%). Among these
were all three major lipids of the inner mitochondrial
membrane, namely PC, PE and CL. Complete reactivation
was achieved by returning phospholipids as detergent–
phospholipid mixed micelles. Although about 80% and
50–70% of the maximal activity were observed with
different crude preparations of soybean phospholipid (aso-
lectins) and highly pure PC or PE, respectively, optimal
reactivation was observed with a mixture of 76% PC, 19%
PE and 5% CL, roughly reflecting the relative abundance
of these lipids in the inner mitochondrial membrane [26].
The specific activity reached by adding a saturating
amount of this lipid mixture varied somewhat between
different batches of protein, but often reached 6–7 Amol
min1 mg1, a value matching the estimated turnover
number of Y. lipolytica complex I in mitochondrial mem-
branes of 110–130 s1 NADH oxidised per molecule of
complex I.
When we titrated the number of phospholipid molecules
needed for maximal reactivation, we found that it also
depended on the composition of the lipid micelles added to
the complex. With neutral PC about 450 lipid molecules
per complex I were sufficient, while almost 900 were
needed if acidic PE was used, which may be explained
by electrostatic repulsion. Four hundred and fifty lipid
molecules are sufficient to form a hydrophobic annulus
around the hydrophobic domain of the complex (dimen-
sions for Y. lipolytica complex I estimated from the
preliminary low-resolution structure derived from single
particle analysis, Zickermann et al., unpublished results),
suggesting that such a layer of phospholipids shields the
hydrophobic regions of the membrane arm from the
aqueous phase and is needed for full activity with hydro-
phobic quinones like DBQ. PC and PE were also proposed
to serve as a ‘solvent’ for ubiquinones in earlier studies
with bovine complex I isolated in cholate [31,33,35]. A
very similar phospholipid dependence was reported for
bovine heart cytochrome bc1 complex purified in Triton
X-100 [36].
A specific cardiolipin requirement was reported for
several complexes of the respiratory chain and the carriers
of the inner mitochondrial membrane (for reviews see Refs.
[26,27,37]). Recently, bound cardiolipin (in addition to one
Fig. 5. Dependence of the NADH:DBQ activity on the amount of added
cardiolipin. Increasing amounts of cardiolipin from bovine heart were
preincubated with 6.8 Ag of purified complex I. Experimental conditions as
indicated in Fig. 2.
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PC, one PI and two PEs) was detected in the structure of the
yeast cytochrome bc1 complex [38], where it might be
involved directly in proton uptake. The precise function of
cardiolipin in complex I from Y. lipolytica is difficult to
assess from our data. Since the highest activities were only
obtained in the presence of cardiolipin (added as purified
phospholipids or as component of asolectin), an essential
role of cardiolipin, be it structural or catalytic, seems
possible. As in earlier studies with the bovine enzyme
[32,33], cardiolipin alone failed to regain full activity,
probably because this phospholipid is not able to build a
regular lipid bilayer, but rather forms precipitates in the
reversed hexagonal state [37].
In summary, we found that the inactivation of complex I
from Y. lipolytica by general delipidation could be fully
reversed simply by returning the phospholipids that had
been removed during the purification procedure. This
demonstrates that our homogeneous and highly pure
enzyme retained its full catalytic potential and that no
specific, functionally essential component had been lost.
Endogenous ubiquinone-9 also turned out to be non-essen-
tial, as the amount still bound was found to be clearly
substoichiometric (0.2–0.4 mol/mol). The latter finding has
some important implications for the catalytic mechanism of
complex I (reviewed in Ref. [12]): as no known prosthetic
group of complex I could be assigned to the membrane
domain of complex I, the nature of the proton pump is still
obscure. Therefore, several authors have proposed that
prosthetic ubiquinone(s) [13,39–41] or a quinoid prosthetic
group ‘X’ [34] are involved in electron transport and the
proton translocation mechanism. Taking its substoichiomet-
ric content in the purified enzyme, endogenous ubiquinone-
9 could only serve as a functional prosthetic group of
complex I, if one assumes that it could be replaced
instantly by added decylubiquinone (the conditions of our
activity measurements). A similar result was obtained by
Fato et al. [42] in investigations with bovine heart sub-
mitochondrial particles: after pentane extraction of most of
the endogenous ubiquinone-10, the complex I-specific
reduction of different quinone substrates (DBQ, CoQ1) still
reached its maximal rate. Based on these and our own
results, it also seems unlikely that any non-covalently
bound endogenous quinone is required for complex I
activity, as one would have expected it to be partially
extracted by the detergent, thereby preventing full reacti-
vation merely by purified phospholipids. For the postulated
but yet unidentified additional prosthetic group, this leaves
a covalently bound quinone or quinoid group as the most
likely alternative.
Acknowledgements
We thank Volker Zickermann and Stefan Kerscher for
carefully reading the manuscript and helpful discussions.
Expert technical assistance from Jolanta Brzoska is
gratefully acknowledged. This work was supported by
grant SFB 472-P2 from the Deutsche Forschungsgemein-
schaft.
References
[1] M.K.F. Wikstro¨m, Nature 308 (1984) 558–560.
[2] A.H. Schapira, Biochim. Biophys. Acta 1364 (1998) 261–270.
[3] B.H. Robinson, Biochim. Biophys. Acta 1364 (1998) 271–286.
[4] R. Djafarzadeh, S. Kerscher, K. Zwicker, M. Radermacher, M.
Lindahl, H. Scha¨gger, U. Brandt, Biochim. Biophys. Acta 1459 (2000)
230–238.
[5] P. Ahlers, K. Zwicker, S. Kerscher, U. Brandt, J. Biol. Chem. 275
(2000) 23577–23582.
[6] P. Ahlers, A. Garofano, S. Kerscher, U. Brandt, Biochim. Biophys.
Acta 1459 (2000) 258–265.
[7] S. Kerscher, N. Kashani-Poor, K. Zwicker, V. Zickermann, U. Brandt,
J. Bioenerg. Biomembranes 33 (2001) 187–196.
[8] N. Kashani-Poor, K. Zwicker, S. Kerscher, U. Brandt, J. Biol. Chem.
276 (2001) 24082–24087.
[9] N. Kashani-Poor, S. Kerscher, V. Zickermann, U. Brandt, Biochim.
Biophys. Acta 1504 (2001) 363–370.
[10] S. Kerscher, S. Dro¨se, K. Zwicker, V. Zickermann, U. Brandt, Bio-
chim. Biophys. Acta, Bioenerg. 1555 (2002) 83–91.
[11] E.V. Gavrikova, V.G. Grivennikova, V.D. Sled, T. Ohnishi, A.D. Vi-
nogradov, Biochim. Biophys. Acta 1230 (1995) 23–30.
[12] U. Brandt, Biochim. Biophys. Acta 1318 (1997) 79–91.
[13] U. Brandt, BioFactors 9 (1999) 95–101.
[14] P.L. Dutton, C.C. Moser, V.D. Sled, F. Daldal, T. Ohnishi, Biochim.
Biophys. Acta 1364 (1998) 245–257.
[15] O.H. Lowry, N.R. Rosebrough, A.L. Farr, R.J. Randall, J. Biol. Chem.
93 (1951) 265–275.
[16] P.S.Chen,T.Y.Toribara,H.Warner,Anal.Chem.28 (1956)1756–1758.
[17] H. Scha¨gger, Th. Hagen, B. Roth, U. Brandt, T.A. Link, G. von
Jagow, Eur. J. Biochem. 190 (1990) 123–130.
[18] A. Kro¨ger, M.E. Klingenberg, Biochem. Z. 344 (1966) 317–336.
[19] M. Takada, S. Ikenoya, T. Yuzuriha, K. Katayama, Biochim. Biophys.
Acta 679 (1982) 308–314.
[20] F.L. Crane, R. Barr, Methods Enzymol. XVIII (1971) 137–165.
[21] S. Kerscher, J.G. Okun, U. Brandt, J. Cell Sci. 112 (1999) 2347–2354.
[22] J.G. Okun, P. Lu¨mmen, U. Brandt, J. Biol. Chem. 274 (1999)
2625–2630.
[23] C.P. Kurtzman, Yeast 10 (1994) 1727–1740.
[24] K.A. Nalecz, R. Bolli, A. Azzi, Methods Enzymol. 126 (1986) 45–64.
[25] D. Cheneval, M.M. Muller, E. Carafoli, FEBS Lett. 159 (1983)
123–126.
[26] G. Daum, Biochim. Biophys. Acta 822 (1985) 1–42.
[27] F.L. Hoch, Biochim. Biophys. Acta 1113 (1992) 71–153.
[28] M. Finel, J.M. Skehel, S.P.J. Albracht, I.M. Fearnley, J.E. Walker,
Biochemistry 31 (1992) 11425–11434.
[29] U. Schulte, V. Haupt, A. Abelmann, W. Fecke, B. Brors, T.
Rasmussen, T. Friedrich, H. Weiss, J. Mol. Biol. 292 (1999) 569–580.
[30] J.G. Okun, V. Zickermann, K. Zwicker, H. Scha¨gger, U. Brandt,
Biochim. Biophys. Acta 1459 (2000) 77–87.
[31] C.I. Ragan, Biochem. J. 172 (1978) 539–547.
[32] M. Fry, D.E. Green, J. Biol. Chem. 256 (1981) 1874–1880.
[33] C. Heron, D. Corina, C.I. Ragan, FEBS Lett. 79 (1977) 399–403.
[34] T. Friedrich, A. Abelmann, B. Brors, V. Guenebaut, L. Kintscher, K.
Leonard, T. Rasmussen, D. Scheide, A. Schlitt, U. Schulte, H. Weiss,
Biochim. Biophys. Acta 1365 (1998) 215–219.
[35] V.M. Poore, C.I. Ragan, Biochim. Biophys. Acta 693 (1982) 105–112.
[36] H. Scha¨gger, Th. Hagen, B. Roth, U. Brandt, T.A. Link, G. von
Jagow, Eur. J. Biochem. 190 (1990) 123–130.
S. Dro¨se et al. / Biochimica et Biophysica Acta 1556 (2002) 65–72 71
[37] W. Dowhan, Ann. Rev. Biochem. 66 (1997) 199–232.
[38] C. Lange, J.H. Nett, B.L. Trumpower, C. Hunte, EMBO J. 20 (2001)
6591–6600.
[39] M. Degli Esposti, A.X. Ghelli, Biochim. Biophys. Acta 1187 (1994)
116–120.
[40] A.D. Vinogradov, J. Bioenerg. Biomembranes 25 (1993) 367–374.
[41] P.L. Dutton, C.C. Moser, V.D. Sled, F. Daldal, T. Ohnishi, Biochim.
Biophys. Acta 1364 (1998) 245–257.
[42] R. Fato, E. Estornell, S. Di Bernardo, F. Pallotti, G.P. Castelli, G.
Lenaz, Biochemistry 35 (1996) 2705–2716.
S. Dro¨se et al. / Biochimica et Biophysica Acta 1556 (2002) 65–7272
